Alnylam Pharmaceuticals, Inc. (ALNY)
333.50
-5.91
(-1.74%)
USD |
NASDAQ |
Apr 15, 16:00
333.50
0.00 (0.00%)
After-Hours: 16:48
Alnylam Pharmaceuticals Research and Development Expense (Annual) : 1.320B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc. | 10.25B |
| Eli Lilly & Co. | 13.34B |
| Ionis Pharmaceuticals, Inc. | 913.18M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Sarepta Therapeutics, Inc. | 1.493B |